These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8244179)

  • 21. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
    Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of imexon in patients with advanced malignancy.
    Dragovich T; Gordon M; Mendelson D; Wong L; Modiano M; Chow HH; Samulitis B; O'Day S; Grenier K; Hersh E; Dorr R
    J Clin Oncol; 2007 May; 25(13):1779-84. PubMed ID: 17470869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible correlation between ormaplatin biotransformations and neurotoxicity.
    Sakata M; Chaney SG; Spriggs DR
    Oncol Res; 1995; 7(2):67-71. PubMed ID: 7579729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
    Winograd B; Vermorken JB; ten Bokkel Huinink WW; Simonetti G; Gall HE; Knobf MK; van der Vijgh WJ; McVie JG; Pinedo HM
    Cancer Res; 1986 Apr; 46(4 Pt 2):2148-51. PubMed ID: 3948186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
    Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
    Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
    Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
    Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
    Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
    Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and safety profile of oxaliplatin.
    Extra JM; Marty M; Brienza S; Misset JL
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):13-22. PubMed ID: 9609104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
    Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
    Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.